|Application ||WB, E|
|Calculated MW||30603 Da|
|Antigen Region||203-232 aa|
|Other Names||CCAAT/enhancer-binding protein epsilon, C/EBP epsilon, CEBPE|
|Target/Specificity||This CEBPE antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 203-232 amino acids from the C-terminal region of human CEBPE.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CEBPE Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional activator (PubMed:26019275). C/EBP are DNA- binding proteins that recognize two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers. Required for the promyelocyte-myelocyte transition in myeloid differentiation (PubMed:10359588).|
|Tissue Location||Strongest expression occurs in promyelocyte and late-myeloblast-like cell lines.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a bZIP transcription factor which can bind as a homodimer to certain DNA regulatory regions. It can also form heterodimers with the related protein CEBP-delta. The encoded protein may be essential for terminal differentiation and functional maturation of committed granulocyte progenitor cells. Mutations in this gene have been associated with Specific Granule Deficiency, a rare congenital disorder. Multiple variants of this gene have been described, but the full-length nature of only one has been determined.
Prasad, R.B., et al. Blood (2009) In press :
Papaemmanuil, E., et al. Nat. Genet. 41(9):1006-1010(2009)
Bedi, R., et al. Blood 113(2):317-327(2009)
Cloutier, A., et al. J. Immunol. 182(1):563-571(2009)
Matsushita, H., et al. Oncogene 27(53):6749-6760(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.